Get the Stockscreener App
1.93
24.35%
0.39
Inmed Pharmaceuticals Inc stock is traded at $1.93, with a volume of 47.91M.
It is up +24.35% in the last 24 hours and up +27.67% over the past month.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
See More
Previous Close:
$1.54
Open:
$2.15
24h Volume:
47.91M
Relative Volume:
21.77
Market Cap:
$10.36M
Revenue:
$3.25M
Net Income/Loss:
$-8.34M
P/E Ratio:
-0.7494
EPS:
-2.5755
Net Cash Flow:
$-7.71M
1W Performance:
+20.44%
1M Performance:
+27.67%
6M Performance:
+78.97%
1Y Performance:
-27.74%
1-Day Range:
$1.82
$2.33
1-Week Range:
$1.49
$2.33
52-Week Range:
$0.575
$2.75
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.9399 | 8.12M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
16.98 | 54.45B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.865 | 44.21B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.89 | 36.10B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.75 | 31.95B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
537.62 | 26.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
Morning Market Movers: INM, INLF, SXTC, ADVB See Big Swings - RTTNews
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline - TradingView
InMed (NASDAQ: INM) outlines Mentari merger structure and names new CEO - Stock Titan
InMed Pharmaceuticals (INM) Gains 1.3% as Stock Approaches Key Resistance LevelForce Index - dars.gov.et
ADAR1 Capital acquires 1,000 InMed common shares worth $1,555 - Bitget
InMed Pharmaceuticals (INM) holder buys 1,000 common shares via ADAR1 - Stock Titan
Vivo Opportunity reports USD 32,319 purchase of InMed common shares - Bitget
Vivo Opportunity funds add 20,546 InMed Pharmaceuticals (INM) shares - Stock Titan
InMed Pharmaceuticals Inc (NASDAQ: INM) Share Price, INM Stock News, INM Share Price & Updates - Kalkine
InMed Pharmaceuticals(INM) Stock Options Chain | Quotes & News - Moomoo
InMed Pharmaceuticals Company Profile & Introduction - Moomoo
InMed Pharmaceuticals and Mentari Therapeutics Amend Merger Agreement and File Registration Statement for Migraine Therapy Deal 1 – Minichart - Minichart
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
InMed amends merger terms, advances Mentari transition - TipRanks
InMed Pharmaceuticals (Nasdaq: INM) refines structure of planned Mentari merger - Stock Titan
InMed Pharmaceuticals Updates Mentari Merger Terms, Adding PIPE Option and Confirming Tax Reorganization - TradingView
InMed Pharmaceuticals (NASDAQ: INM) clarifies Mentari merger structure and targets Q4 2026 closing - Stock Titan
Enterprise value to EBIT forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics - Moomoo
InMed Pharmaceuticals (INM) Moves Forward with Merger Agreement Amendments - GuruFocus
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 - TMX Newsfile
InMed Pharmaceuticals (INM) Stages 7% Advance: Testing Key Resistance LevelPut Dominated - DonanımHaber
InMed Pharmaceuticals และ Mentari Therapeutics ประกาศแก้ไขข้อตกลงการควบรวมกิจการ พร้อมยื่นแบบแสดงรายการข้อมูลการจดทะเบียน (Registration Statement) ตามแบบ Form S-4 - Moomoo
InMed Pharmaceuticals (INM) Slips 1.89% as Shares Test Key Support at $1.48Counter Trend Trade - dars.gov.et
INMInMed Pharmaceuticals Inc Forecast, Target Price - Finviz
Vivo Opportunity increases InMed (INM) stake with open-market share buys - Stock Titan
InMed (INM) to merge with Mentari after $290M financing; Exchange ~2.0606 - Stock Titan
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Continued R&D Progress Amid No RevenueEnergy Earnings Report - DonanımHaber
Price to sales forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Price to earnings forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Enterprise value to revenue forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:INM) - TradingView
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals Inc. Cash Flow – DUS:MWG - TradingView
Dilution adjustment of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Current ratio of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Total revenue of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Basic earnings per share (basic EPS) of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
MWG Stock Price and Chart — DUS:MWG - TradingView
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Valuation: PE, PB & Fair Value Analysis - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moderna to Host Investor EventScience Day - Investing News Network
InMed Pharmaceuticals (INM) Slides to $1.5 as Traders Eye Support at $1.42RTH Profile - dars.gov.et
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inmed Pharmaceuticals Inc Stock (INM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10% Owner |
Jul 15 '26 |
Buy |
1.55 |
15,150 |
23,482 |
743,038 |
| Vivo Opportunity, LLC | 10% Owner |
Jul 14 '26 |
Buy |
1.55 |
5,375 |
8,331 |
729,277 |
| Vivo Opportunity, LLC | 10% Owner |
Jul 16 '26 |
Buy |
1.55 |
21 |
33 |
743,057 |
| Vivo Opportunity, LLC | 10% Owner |
Jul 01 '26 |
Buy |
1.55 |
4,344 |
6,733 |
722,935 |
| Vivo Opportunity, LLC | 10% Owner |
Jul 02 '26 |
Buy |
1.55 |
1,607 |
2,491 |
724,395 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 30 '26 |
Buy |
1.54 |
600 |
924 |
718,989 |
| Vivo Opportunity, LLC | 10% Owner |
May 20 '26 |
Buy |
1.56 |
56,210 |
87,688 |
543,129 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 05 '26 |
Buy |
1.57 |
55,011 |
86,367 |
688,926 |
| Vivo Opportunity, LLC | 10% Owner |
May 21 '26 |
Buy |
1.69 |
34,000 |
57,460 |
574,011 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 08 '26 |
Buy |
1.52 |
32,500 |
49,400 |
718,444 |
0.64%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):